Venous Ethanol for Ventricular Tachycardia

Who May Qualify: - Male and female, ages of 18 and 85 years and with a prior ICD implant - Diagnosed with ischemic cardiomyopathy: Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause) - One of the following VT events (within last 6 months): a) ≥3 episodes of VT treated with anti-tachycardia pacing (ATP) or anti-arrhythmic drugs; b) ≥1 appropriate ICD shocks; c) ≥3 VT episodes within 24 hr; d) sustained VT below detection rate of the ICD documented by EKG/cardiac monitor - Patients deemed candidates for RF ablation of VT - Able and willing to comply with pre-, post-, and follow-up requirements - Willing to sign the willing to sign a consent form Who Should NOT Join This Trial: - Serum creatinine \>1.5 mg/dL, or creatinine clearance \<30 ml/min - Left ventricular (LV) ejection fraction ≤10% - Mobile LV thrombus on echocardiography - Absence of vascular access to the LV - Disease process likely to limit survival to \<12 months - New York Heart Association class IV heart failure - Cardiac surgery within the past 2 months (unless VT was incessant), - Acute coronary syndrome in the past 2 months (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on EKG) - Another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia) - Severe aortic stenosis or mitral regurgitation with a flail leaflet - Pregnancy - Unwilling or unable to provide willing to sign a consent form - Covid-19 positive testing within 14 days of randomization procedure - Enrolled, or planning to get enrolled, in another research study during his/her participation on the Velvet trial Always talk to your doctor about whether this trial is right for you.